Australia Health

Paradigm Biopharmaceuticals (ASX:PAR) has agreed to return US$2 million to Obsidian Global GP and cancel 2,000,000 convertible notes.

Nexsen (ASX:NXN) paused its StrepSure clinical trial for product enhancements, which the company expects will delay regulatory submission by one quarter.

Ovarian cancer diagnostics company Cleo Diagnostics (ASX:COV) has commenced prototype development of a multi-biomarker blood test.

Paradigm Biopharmaceuticals (ASX:PAR) has missed a key efficacy threshold in its Phase 3 trial for knee osteoarthritis.

BCAL Diagnostics (ASX:BDX) has commenced the Australian rollout of the Avantect Multi-Cancer blood-based diagnostic test in Sydney and Melbourne.

Prescient Therapeutics (ASX:PTX) completed a $6 million capital raise to advance the clinical development of its target cancer therapy.

Patrys (ASX:PAB) has commenced human clinical testing by dosing the first participants in a Phase 1a trial for RLS-2202.

Dimerix (ASX:DXB) has drawn down $17 million under a non-dilutive debt facility to fund its key clinical pipeline.

Seven Australian startups have secured $15.6 million in non-dilutive federal funding to commercialise dementia diagnostics, therapies, and digital tools.

Genetic Signatures (ASX:GSS) has agreed on commercial terms to acquire Microba Life Sciences (ASX:MAP).

Rhythm Biosciences (ASX:RHY) completed the first phase of its ColoSTAT technology transfer and assessment with a National Health Service laboratory.

Neurotech International (ASX:NTI) has dosed the first patient in its pivotal Phase 3 "Beyond Harmony" clinical trial.